유타의 전이성 암 임상 시험
전이성 암 관련 연구 27개가 유타 내 여러 지역에서 참여자를 모집하고 있습니다.
유타의 도시
공식 연구 텍스트(영어)
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
- Clinical Study Site, West Valley City
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 11. 13. 업데이트됨 · NCT07335497A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- START Mountain Region, West Valley City
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT06270706A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Huntsman Cancer Institute, University of Utah, Salt Lake City
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT07458347A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Huntsman Cancer Institute, Salt Lake City
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 11. 10. 업데이트됨 · NCT07020221A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Intermountain Health, Salt Lake City
피험자 모집 중1상
19세 이상 · 모든 성별 · 2026. 11. 5. 업데이트됨 · NCT06586957A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- South Texas Accelerated Research Therapeutics (START) Mountain Region, West Valley City
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 5. 업데이트됨 · NCT07029399A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Utah Cancer Specialists, Salt Lake City
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT07174336A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University of Utah - Huntsman Cancer Institute, Salt Lake City
- START Mountain Region, West Valley City
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT06465069A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Huntsman Cancer Institute, Salt Lake City
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT07213804FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- University of Utah, Salt Lake City
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT05614739Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
- Start Center for Cancer Research - Mountain Region, West Valley City
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 3. 업데이트됨 · NCT05856981Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Huntsman Cancer Institute, University of Utah, Salt Lake City
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 10. 30. 업데이트됨 · NCT06943755A Study of MGC026 in Participants With Advanced Solid Tumors
- START Mountain Region, West Valley City
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 28. 업데이트됨 · NCT06242470AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, West Valley City
피험자 모집 중1/2상
18세 ~ 75세 · 모든 성별 · 2026. 10. 16. 업데이트됨 · NCT07038343First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
- Huntsman Cancer Institute, University of Utah, Salt Lake City
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 15. 업데이트됨 · NCT05875168A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
- START Mountain Region, West Valley City
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 13. 업데이트됨 · NCT06880549Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Huntsman Cancer Institute, University of Utah, Salt Lake City
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 8. 업데이트됨 · NCT07222566A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
- ALX Center 4, West Valley City
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT07085091A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- START Mountain Region, LLC, West Valley City
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT07277413Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- University of Utah - Huntsman Cancer Institute, Salt Lake City
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 18. 업데이트됨 · NCT05267626Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
- Huntsman Cancer Institute/University of Utah, Salt Lake City
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 3. 업데이트됨 · NCT05687110A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- Huntsman Cancer Institute, University of Utah, Salt Lake City
- START Mountain Region, LLC., West Valley City
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 7. 15. 업데이트됨 · NCT06657144BBO-11818 in Adult Subjects With KRAS Mutant Cancer
- Huntsman Cancer Institute, Salt Lake City
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 6. 2. 업데이트됨 · NCT06917079Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Huntsman Cancer Institute, Salt Lake City
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 5. 15. 업데이트됨 · NCT05379985Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- START Mountain Region, West Valley City
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 2. 18. 업데이트됨 · NCT07030257Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors
- Huntsman Cancer Institute at University of Utah, Salt Lake City
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 2. 13. 업데이트됨 · NCT06358677SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Salt Lake City
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2025. 10. 28. 업데이트됨 · NCT03452774ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.